Boulder, Colorado, United States, October 2025 – Jean-Pierre Wery has been appointed as the new Chief Executive Officer of Mosaic Biosciences. With an extensive career spanning more than three decades across drug discovery, structural biology, and executive leadership, he will lead the company’s vision of transforming early-stage concepts into innovative drug candidates. At Mosaic, he is expected to strengthen strategic direction, accelerate protein therapeutic development, and drive innovation in collaboration with the company’s multidisciplinary teams.
Jean-Pierre Wery most recently served as President and CEO of Sidewinder Therapeutics, where he led the company’s growth and development of novel therapeutic solutions. His leadership enabled Sidewinder to expand its innovation pipeline while solidifying its reputation in the biopharma sector.
Before his role at Sidewinder, Wery dedicated nearly 15 years to Crown Bioscience, where he progressed through roles as President, CEO, and ultimately Executive Chairman. During this period, he was instrumental in shaping the company’s global strategy, advancing R&D capabilities, and expanding market presence. His concurrent role as Chief Technology Officer at JSR Life Sciences underscored his ability to bridge scientific innovation with commercial success.
Earlier in his career, he served as Chief Scientific Officer at Monarch LifeSciences, driving the company’s R&D agenda and supporting sales and marketing efforts. At Vitae Pharmaceuticals, he was Vice President of Drug Discovery, where he led efforts in discovery sciences and early-stage drug development.
Wery’s foundation in leadership was built at Eli Lilly & Co., where he held significant responsibilities including Head of Global Statistics & Information Sciences and Head of Computational Chemistry & Molecular Structure Research, advancing drug discovery platforms and computational approaches.
He began his academic journey with a PhD in Physics from the University of Liège, followed by a Postdoctoral fellowship in Structural Biology at Purdue University, where he specialized in structural biology and virology, laying the groundwork for his impactful career in biopharma.
About Mosaic Biosciences
Mosaic Biosciences transforms concepts into drug candidates with end-to-end discovery capabilities and a first-class multidisciplinary team. The company offers experienced biopharma leadership and integrated cross-functional expertise to accelerate the research and development of protein therapeutics. With a focus on innovative science and strategic execution, Mosaic Biosciences partners with clients to advance breakthrough therapies that address critical unmet medical needs.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
